Armstrong Pharmaceuticals
United States 44 employees Updated 9 July 2026
Armstrong Pharmaceuticals is a finished-dose manufacturer based in United States. It appears in 3 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 19 July 2024 as VAI.
1
registered plants
1 with an FDA FEI number
3
filings
across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 19 July 2024 VAI US FDA
- 14 July 2021 NAI US FDA
- 3 April 2014 NAI US FDA
- 5 October 2012 NAI US FDA
- 14 June 2012 VAI US FDA
- 11 December 2009 NAI US FDA
- 13 November 2009 VAI US FDA
- 29 September 2009 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Canton, United States | 3007009553 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | 3 | 1 |
Comparing suppliers?
Choose your molecules and target markets. Armstrong Pharmaceuticals comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 19 July 2024.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates